Skip to main content
SpringerLink
Log in

Author’s Reply to Proost: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients”

  • Reply
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

The Original Article was published on 15 December 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Proost JH. Comment on: "Challenges in individualizing drug dosage for intensive care unit patients". [letter]. Clin Pharmacokinet.

  2. Jelliffe R. Challenges in individualizing drug dosage for intensive care unit patients: is augmented renal clearance what we really want to know? Some suggested management approaches and clinical software tools. Clin Pharmacokinet. 2016;55(8):897–905. doi:10.1007/s40262-016-0369-4.

    Article  CAS  PubMed  Google Scholar 

  3. D’Argenio D. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharmacol. 1981;9:739–56.

    Article  Google Scholar 

  4. Bayard D, Jelliffe R, Neely M. Bayes risk as an alternative to fisher information in determining experimental designs for nonparametric models [slides and abstracts]. Population Optimal Design of Experiments Conference, Lilly Laboratories, Erl Wood Manor, Windesham, Surrey, UK, June 15, 2013. http://www.maths.qmul.ac.uk/~bb/PODE/PODE2013_Slides/PODE2013_RogerJelliffe.pdf. Accessed 8 Dec 2016.

  5. Jelliffe R, Bayard D, Neely M. MMopt—an optimal TDM protocol strategy based on Bayes risk and weighted Bayes risk [oral presentation]. In: 14th congress of the international Association for Therapeutic Drug Monitoring and Clinical Toxicology, 14 Oct 2015, Rotterdam.

  6. Bayard D, Jelliffe R. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn. 2004;31(1):75–107.

    Article  PubMed  Google Scholar 

  7. Blom HAP. An efficient filter for abruptly changing systems [abstract]. In: 23rd IEEE conference on decision and control, 12–14 Dec 1984, Las Vegas.

  8. Blom HAP, Bar-Shalom Y. The interacting multiple model algorithm for systems with Markovian switching coefficients. IEEE Trans Autom Control. 1988;33:780–3.

    Article  Google Scholar 

  9. Macdonald I, Staatz C, Jelliffe R, Thomson A. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit. 2008;30:67–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jelliffe R. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol. 2002;22:320–4.

    Article  PubMed  Google Scholar 

  11. Jelliffe R. Optimal methodology is important for optimal pharmacokinetic studies, therapeutic drug monitoring, and patient care [commentary]. Clin Pharmacokinet. 2015;54(9):887–92. doi:10.1007/s40262-015-0280-4.

    Article  PubMed  Google Scholar 

  12. Goodwin G, Payne R. Dynamic system identification: experiment design and data analysis. New York: Academic Press; 1977. p. 50 (Theorem 3.4.1).

    Google Scholar 

  13. Rowland M, Benet L, Graham G. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973;1(2):123–36.

    Article  CAS  PubMed  Google Scholar 

  14. Mehvar R. The relationship among pharmacokinetic parameters: effects of altered kinetics on the drug plasma concentration-time profiles. Am J Pharm Educ. 2004;68(2):1–9.

    Google Scholar 

  15. Jelliffe R, Neely M, editors. Individualized drug therapy for patients: basic foundations, relevant software and clinical applications. 1st ed. Elsevier.

Download references

Author information

Authors and Affiliations

  1. Laboratory of Applied Pharmacokinetics and Bioinformatics, Children’s Hospital of Los Angeles, University of Southern California School of Medicine, 4650 Sunset Boulevard, #51, Los Angeles, CA, 90027, USA

    Roger W. Jelliffe

Authors
  1. Roger W. Jelliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger W. Jelliffe.

Ethics declarations

Conflict of interest

R. Jelliffe has no conflicts of interest to declare. No funding was received in the preparation of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jelliffe, R.W. Author’s Reply to Proost: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients”. Clin Pharmacokinet 56, 313–316 (2017). https://doi.org/10.1007/s40262-016-0482-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-016-0482-4

Keywords

Search

Navigation